MSD France

What MSD France does

MSD France is the French subsidiary of Merck & Co., Inc. (NYSE: MRK), operating as a Société par Actions Simplifiée (SAS) headquartered in Puteaux, Île-de-France. The company markets prescription medicines and vaccines across four therapeutic areas: oncology (including immunotherapy), infectious diseases (HIV, antibiotics), vaccines (HPV, Ebola), and cardiovascular conditions. Approximately 850 employees support commercial operations, field sales, medical affairs, and clinical research, with the headquarters housed in an HQE-certified eco-responsible building. The company is recognized as the leading European subsidiary for clinical research and second globally after the United States, conducting 138 clinical studies with nearly 3,000 patients enrolled and operating through nearly 1,000 clinical investigation centers and 186 academic cohorts across France.

The business model centers on the sale of regulated pharmaceutical products through field sales representatives targeting healthcare professionals, hospital pharmacies, and retail pharmacies, supported by Medical Science Liaisons and the MSDConnect digital platform. MSD France runs complementary direct-to-patient digital channels including Mon-Cancer.com (cancer patient portal), Papillomavirus.fr (HPV awareness site), and a public clinical trial search engine. R&D investment in France totaled 120 million euros in 2021, supplementing the parent's commitment of 25% of global revenue to research. The MSDAVENIR research support fund — the first of its kind in French life sciences — has disbursed 117 million euros in endowments and produced 18 patent filings over 7 years. The MSD SMART antimicrobial resistance surveillance program tracks approximately 500,000 bacterial isolates from 217 sites in 63 countries. Partnerships include Klineo (clinical trial matching), IFEP (patient experience), Courir pour Elles (cancer prevention), and the Bill & Melinda Gates Foundation (HIV PrEP development). Recent recognitions include Great Place to Work certification (3 consecutive years), Best Workplaces for Women (3 consecutive years), EcoVadis Silver Medal (2023), and Gender Equality Index scores of 96-98/100 across 7 consecutive years.

Name

MSD France

Legal name

MSD France

Website

https://msd-france.com

Company type

Private

Founded year

1894

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

MSD France is the French subsidiary of Merck & Co., Inc., selling prescription medicines and vaccines in oncology, infectious diseases, and vaccines through field sales, hospital channels, and digital platforms serving healthcare professionals, patients, and academic centers.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals & Vaccines

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

akta.pro secondary industries

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Prescription pharmaceuticals
• Vaccines research
• Oncology immunotherapy
• Clinical research trials
• Infectious disease therapies

Headquarters

HQ city

Puteaux

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Products and Vaccines: MSD France generates revenue through the sale of prescription medicines and vaccines across therapeutic areas including oncology, infectious diseases (VIH, antibiotics), and vaccines (HPV, Ebola). The company invests 25% of global revenue in R&D.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

MSD France is a research-based pharmaceutical laboratory that develops, registers, and commercializes prescription medicines and vaccines across oncology (with leadership in immunotherapy), infectious diseases (HIV, antibiotics), and vaccines (HPV, Ebola). The company operates a substantial clinical research infrastructure in France with 138 ongoing clinical studies and nearly 1,000 clinical investigation centers, while supporting healthcare professionals and patients through dedicated digital platforms and research funding programs.

Product overview

MSD France is a global pharmaceutical company (subsidiary of Merck & Co., Inc.) with over 130 years of history, operating as a research-based pharmaceutical laboratory. The company's product portfolio spans four main therapeutic areas: Oncology (including immunotherapy), Infectious Diseases (HIV, antibiotics), Vaccines (HPV, Ebola), and cardiovascular diseases. The offering combines traditional pharmaceutical products with digital patient and healthcare professional services including MSDConnect (professional platform), patient information portals (Mon-Cancer.com, Papillomavirus.fr), clinical trial search engines, and the MSDAVENIR research fund supporting French scientific research with 117M EUR in endowments.

Differentiator

Problem solved

Functional benefit

Brands

• MSDConnect: Professional portal for healthcare professionals providing information and services
• Mon-Cancer.com
• Papillomavirus.fr
• MSDAVENIR
• MSD SMART
• MSD Fellowship for Global Health

Products and services

• MSDConnect Healthcare professional information and services platform providing dedicated space for medical information, services designed to enrich daily practice and improve patient care management.

Quantifiable outcome

• 138 clinical studies conducted in France, enabling nearly 3,000 patients to access innovative molecules
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• KlineocoreStrategic or Co-development Partner · 18 July 2023French startup partnership to improve access to oncology clinical trial information. Klineo's innovative digital platform uses algorithms to match patients with clinical trials and connects patients with clinical investigation sites. Initially focused on triple-negative breast cancer, partnership expanded to all indications on the Klineo platform, serving 1,500 healthcare professionals and 3,000 patients.
• IFEP (Institut Français de l'Expérience Patient)coreStrategic or Co-development PartnerPartnership with French patient experience institute to develop patient-centered initiatives in healthcare settings. Collaboration aims to integrate patient voices in care organization and produce educational content, including the P+S video series on diagnosis communication in oncology.
• Courir pour EllescoreGTM or Marketing PartnerHistorical partnership since 2010 supporting cancer prevention through sports. MSD France sponsors annual Courir pour Elles event to raise awareness about HPV-related cancer risks and prevention methods including vaccination and screening.
• Laurette FugainminorGTM or Marketing PartnerPartnership with blood and bone marrow donation association to promote life-saving donations and raise awareness about blood cancers including leukemia. MSD France labeled 'Entreprise ambassadrice des dons de vie' under Leem Group Impact and Laurette Fugain association.
• ELSANminorImplementation/ SI/ Consulting PartnerPrivate hospital group providing workplace vaccination services for MSD France employees. ELSAN conducts HPV vaccination campaigns in company premises for employees up to 26 years old.
• ANAPIX MedicalminorImplementation/ SI/ Consulting PartnerMedical company conducting early melanoma detection sessions at MSD France headquarters and for field teams, providing skin cancer screening services.
• Association TulipeminorGTM or Marketing PartnerEmergency and international solidarity association of healthcare companies federating donations to respond to population needs in distress. MSD France donated perfusion kits worth over 200,000 euros, part sent to Ukraine.
• Bill and Melinda Gates FoundationcoreStrategic or Co-development PartnerInternational research partnership for pre-exposure prophylaxis (PrEP) development in HIV prevention targeting sub-Saharan Africa populations.
• MSDAVENIRcoreStrategic or Co-development PartnerFirst research support fund in France in life sciences, created by MSD. Disbursed 117 million euros in endowment and enabled 18 patent filings in 7 years. Supports academic research and public-private partnerships.
• TélémaqueminorGTM or Marketing PartnerMentoring program partnership supporting high-potential students from priority education schools (REP). MSD employees accompany young people through mentorship activities.
• Article 1minorGTM or Marketing PartnerAssociation promoting equal opportunities through mentoring. MSD France employees mentor young people from underprivileged backgrounds as part of corporate social responsibility initiatives.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Novartis: Operates a French subsidiary covering oncology, infectious diseases and vaccines, with comparable clinical research infrastructure and HCP-facing digital platforms, making it a directly comparable global pharma peer with French market overlap.
• GSK: Global vaccines leader (HPV, meningitis) with French operations, competing head-to-head with MSD France in HPV vaccination and infectious disease therapeutics, with comparable clinical research and HCP engagement infrastructure.
• Sanofi: Headquartered in Paris and operating across vaccines (Sanofi Pasteur), oncology, and infectious diseases, Sanofi is the most direct competitor to MSD France in the French market with overlapping therapeutic areas and similar field-sales-driven commercialization.
• Bristol-Myers Squibb: Direct competitor in immuno-oncology with French commercial operations, overlapping clinical trial activity in oncology, and similar reliance on field sales and MSL engagement to reach specialist HCPs.
• Roche: A global pharmaceutical leader with major oncology presence (Genentech) and significant French commercial operations, Roche competes directly with MSD France's immunotherapy franchise and shares a similar mix of in-country clinical research and HCP engagement.
• Pfizer: Competes with MSD France in vaccines (including HPV) and oncology through its French subsidiary, with similar field sales reach to HCPs, comparable clinical trial footprint, and overlapping patient education initiatives.
• Ipsen: French specialty pharma (headquartered in Paris area) focused on oncology, neuroscience and rare diseases, with comparable French commercial operations and clinical research engagement in the same academic hospital network.
• AstraZeneca: Strong oncology and vaccines franchise with a French subsidiary directly competing with MSD France's immuno-oncology pipeline and HPV/COVID vaccine portfolio, using comparable field-sales and clinical research models.
• Servier: French-headquartered independent pharmaceutical company with significant oncology and cardiovascular presence, comparable in-country commercial footprint, and similar reliance on clinical research partnerships within French academic centers.

Emerging players

• BioNTech: German biotech with significant vaccine and immuno-oncology pipeline, partnering with major pharma for commercialization and increasingly overlapping MSD France's vaccine and oncology research domains from a European base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCqjB4FDHll0sA-glDxQdOzg
• LinkedInlinkedin.com/company/msd-france

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD France